Oncology and Hematology - Global Oncology Academy

305-320 of 789

The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
MinuteCE®
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
A.J. Gelderblom, MD, PhD
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Project Oncology®
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Casey Cosgrove, MD
- Casey Cosgrove, MD
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Project Oncology®
Growth Recovery After Tovorafenib in Pediatric Low-Grade Gliomas: New Data
Alexandria May, PharmD, BCPS; Daniel Landi, MD
- Alexandria May, PharmD, BCPS
- Daniel Landi, MD
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Project Oncology®
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Victoria Coleman-Cowger, PhD
- Victoria Coleman-Cowger, PhD
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Project Oncology®
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Brian Slomovitz, MD
- Brian Slomovitz, MD
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Project Oncology®
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Brian Slomovitz, MD
- Brian Slomovitz, MD
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Project Oncology®
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Ryan Quigley
- Ryan Quigley
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Ryan Quigley
- Ryan Quigley
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Project Oncology®
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Project Oncology®
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Casey Cosgrove, MD
- Casey Cosgrove, MD
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Ryan Quigley
- Ryan Quigley
Routes Reconsidered: A Case-Based Debate in SERD Selection
Routes Reconsidered: A Case-Based Debate in SERD Selection
MinuteCE®
Routes Reconsidered: A Case-Based Debate in SERD Selection
Giuseppe Curigliano, MD, PhD; Komal Jhaveri, MD, FACP
1.00 program credit
- Giuseppe Curigliano, MD, PhD
- Komal Jhaveri, MD, FACP
1.00 program credit
Spotlight on Europe: Adapting the Evidence
Spotlight on Europe: Adapting the Evidence
MinuteCE®
Spotlight on Europe: Adapting the Evidence
Giuseppe Curigliano, MD, PhD
1.00 program credit
- Giuseppe Curigliano, MD, PhD
1.00 program credit
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
MinuteCE®
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Giuseppe Curigliano, MD, PhD
1.00 program credit
- Giuseppe Curigliano, MD, PhD
1.00 program credit
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
MinuteCE®
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Komal Jhaveri, MD, FACP
1.00 program credit
- Komal Jhaveri, MD, FACP
1.00 program credit

20/11